Veeva MedTech Sets a New Benchmark in Clinical Trials
The medtech sector is undergoing significant transformation as over 50 medical technology companies embrace the innovative Veeva Clinical Platform. This change comes amidst growing regulatory demands and the evolving landscape of medical devices and diagnostics. Notably, 11 of the top 20 medtech companies and seven out of the top 10 clinical research organizations (CROs) are at the forefront of this transition.
In a world where efficiency is paramount, Veeva's platform aims to break down the long-standing barriers of legacy systems. By integrating modern, connected applications, companies can streamline their clinical trials, taking advantage of rapid scalability while ensuring compliance across various regulatory frameworks. For instance, Veeva EDC customers are reporting study build times that are 50% faster. Concurrently, Veeva eTMF users have noted an impressive 80% reduction in redundant documentation—a testament to the platform’s effectiveness.
Kevin Liang, the vice president of clinical strategy at Veeva MedTech, remarked, "It’s exciting to partner with the industry as it transitions to Veeva MedTech. Our goal is to create a fully interconnected infrastructure for clinical trials that encompasses medical devices and diagnostics alike. This will foster collaboration and innovation, allowing life-changing products to reach patients more swiftly."
Industry Voices on Veeva’s Impact
The reaction from industry leaders has been overwhelmingly positive.
Alcon’s head of clinical data operations, Leianne Ebert, shared, "Collaborating closely with Veeva EDC has enabled our team to enhance our global library and establish reusable standards. Our focus on standardization bore fruit—achieving 50% in one year boosted our compliance dramatically across the board."
Similarly, Kimberly Dorsch, the VP of global clinical affairs at LifeNet Health, stated, "Veeva enables us to gather study data in a consistent manner, ensuring that it meets the regulatory criteria. Whether dealing with registry studies or IDE/IND trials supporting PMAs/BLAs, compliance is maintained throughout."
Smith+Nephew has also seen major improvements since integrating Veeva eTMF. According to their senior VP, Matt Christensen, "Since the adoption of Veeva eTMF, we’ve slashed our quality control time by over 90%, while also significantly reducing the time needed for document creation."
A Bright Future with Veeva MedTech
As more medtech entities recognize the benefits of Veeva's Clinical Platform, the industry is set to experience accelerated growth and innovation. By opting for Veeva, companies are not only prioritizing efficiency but also aligning themselves with modern best practices that promote quality and compliance within clinical trials.
For further details on how Veeva is pioneering change in clinical trials for medtech, visit
veeva.com/MedTechClinical.
About Veeva Systems
Veeva is acknowledged as the preeminent leader of cloud-based software tailored for the life sciences industry. With a steadfast commitment to innovation and customer success, Veeva serves an extensive range of clients, from the largest biopharmaceutical firms to up-and-coming biotech enterprises. As a Public Benefit Corporation, Veeva strives to balance the interests of all its stakeholders, including customers, employees, shareholders, and the broader industry ecosystem. For more information, please visit
veeva.com.
This release may contain forward-looking statements regarding Veeva's offerings and anticipated benefits. Actual outcomes could diverge materially. The risks outlined in Veeva's filings, including their quarterly Form 10-Q for the period ending April 30, 2025, can be explored further at sec.gov.